Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAid GBM Pilot Study
NCT07908147Phase 1Not yet recruiting
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Mar 2027
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of plixorafenib, larotrectinib and cadonilimab in glioblastoma (GBM) (3 arms), sponsored by Olivia Newton-John Cancer Research Institute. Primary endpoint: Feasibility of Rapid Molecular Profiling and Matched Targeted Therapy. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
plixorafeniblarotrectinibcadonilimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07908147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908147.